Document Detail


Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease.
MedLine Citation:
PMID:  22738665     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: To determine gastrointestinal (GI) toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease (IBD). METHODS AND MATERIALS: We retrospectively reviewed 13 patients diagnosed with IBD from a cohort of over 3200 patients with low- to intermediate-risk prostate cancer treated with (125)I brachytherapy (144Gy). Acute (i.e. <12 months) and late lower GI toxicity after brachytherapy using the Radiation Therapy Oncology Group (RTOG) grading system was assessed. Possible factors (e.g. patient, treatment, dosimetry, and characteristics of IBD) influencing GI toxicity were assessed. RESULTS: Median followup was 4.2 years. Ten patients had ulcerative colitis (UC) and 3 had Crohn's disease. Seven patients with UC had known involvement of the rectum. Acute RTOG GI Grade 0, 1, 2, 3, 4 toxicity was seen in 7, 1, 2, 2, 1 patients, respectively. The corresponding late RTOG GI toxicity was seen in 7, 1, 3, 1, 1 patients, respectively. Two patients required major surgery. All patients with severe GI toxicity (i.e., Grade ≥3) had UC with disease involving the rectum and underwent endoscopic biopsies of the rectum within 3 months after the implant. There was no clear association with other factors with toxicity. CONCLUSIONS: Twenty-three percent and 15% patients with IBD experienced Grade 3 or higher acute and late GI toxicity, respectively, after brachytherapy. Prostate brachytherapy should be used with great caution or avoided, particularly for men with active IBD involving the rectum. Biopsies of the rectum after brachytherapy should be avoided as it may lead to ulceration.
Authors:
Howard H Pai; Mira Keyes; W James Morris; Jennifer Christie
Related Documents :
22843265 - Hexanucleotide repeat expansions in c9orf72 in the spectrum of motor neuron diseases.
11459615 - Measurement of ataxic symptoms with a graphic tablet: standard values in controls and v...
21975205 - Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.
21913425 - The role of elastography in the differential diagnosis of endometrial pathologies--prel...
20310015 - Mucosal healing in patients with ulcerative colitis during a course of selective leukoc...
8908975 - The broadened framework of compulsory interventions in the new israeli law. their pract...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-25
Journal Detail:
Title:  Brachytherapy     Volume:  -     ISSN:  1873-1449     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101137600     Medline TA:  Brachytherapy     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Affiliation:
Radiation Oncology Program, British Columbia Cancer Agency-Vancouver Island Centre, Victoria, British Columbia, Canada; Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Which characteristic of Natto: appearance, odor, or taste most affects preference for Natto.
Next Document:  Bioinspired Morphogenesis of Highly Intricate and Symmetric Silica Nanostructures.